Hong Kong, November 17, 2026
Ascletis Pharma Inc. has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for ASC36_37o FDC, an investigational once-weekly oral fixed-dose combination (FDC) designed to treat obesity. The experimental therapy is being developed as a potentially first-in-class oral quadruple peptide agonist targeting four validated obesity-related pathways: the amylin receptor, GLP-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR). The combination brings together two peptide candidates, ASC36 and ASC37, in a single tablet, representing an advancement in Ascletis’ oral peptide drug development strategy. The company aims to develop a convenient, less frequently administered oral treatment option for people living with obesity. The IND submission marks an important regulatory milestone for the company’s metabolic disease pipeline and supports the potential clinical development of its innovative peptide combination.
ASC36_37o FDC Combines Four Validated Obesity Targets
ASC36_37o FDC combines ASC36, an amylin receptor peptide agonist, with ASC37, a triple peptide agonist targeting GLP-1R, GIPR and GCGR. By combining these two investigational candidates, Ascletis aims to address four biological pathways associated with appetite regulation, energy balance and metabolic function through one oral fixed-dose formulation. According to the company, this is potentially the first once-weekly oral fixed-dose combination designed to target all four pathways in a single tablet. Both peptide candidates were discovered internally using Ascletis’ Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) technology. The development of the combination also relies on the company’s proprietary Peptide Oral Transport ENhancement Technology (POTENT) platform, which is designed to improve the absorption of orally administered peptides. The platform aims to support absorption through both gastric and intestinal sites while reducing pharmacokinetic variability between and within individuals. This technology is particularly relevant to peptide therapeutics, which can present challenges when administered orally because of degradation and limited absorption in the gastrointestinal tract.
Preclinical Results Demonstrate Extended Half-Life and Weight Reduction
In non-human primate studies, ASC36_37o FDC demonstrated half-lives of up to 200 hours for ASC36 and 96 hours for ASC37, equivalent to approximately 8.3 days and four days, respectively. The combination also demonstrated oral bioavailability exceeding 10% for ASC36 and at least 9.1% for ASC37. According to Ascletis, combining the two peptides in one formulation extended ASC36’s half-life from approximately seven days when administered as a single agent to approximately 8.3 days in the fixed-dose combination. Its oral bioavailability also increased compared with the single-agent formulation. In separate head-to-head studies involving diet-induced obese rats, the co-formulation achieved approximately 69% greater body-weight reduction compared with ASC37 monotherapy and approximately 192% greater reduction compared with ASC36 monotherapy. These findings provide preclinical evidence supporting further investigation of the combination. However, the results were generated in animal studies and should not be interpreted as demonstrated weight-loss benefits in humans. The safety, tolerability, efficacy and appropriate dosing of ASC36_37o FDC will require evaluation through clinical trials.
FDA IND Submission Strengthens Ascletis’ Obesity Pipeline
The IND submission builds on Ascletis’ ongoing development of once-weekly oral peptide therapies. The company has recently initiated a U.S. Phase I clinical study of ASC36o, its once-weekly oral amylin receptor peptide agonist, with initial human pharmacokinetic data expected by the end of 2026. The company believes that the combination of long-acting peptide candidates and its proprietary oral delivery technology could support the development of differentiated treatment options for obesity and other metabolic conditions. Ascletis is also advancing a broader pipeline of investigational therapies targeting GLP-1R, GIPR, GCGR and amylin pathways, including oral small molecules, injectable peptides and combination therapies. Its lead program, ASC30, a once-daily oral small-molecule GLP-1 receptor agonist, is being evaluated in two global Phase III studies for obesity. The latest IND submission further expands the company’s research into multi-target metabolic therapies and demonstrates its continued investment in innovative drug discovery and development. Although ASC36_37o FDC remains investigational and has not received FDA approval, its progression toward clinical evaluation represents an important development in the search for convenient, long-acting oral obesity treatments. Future clinical studies will be essential to determine whether its promising preclinical characteristics translate into meaningful benefits for patients.
Source: Ascletis Pharma press release



